Monograph Details
|
|
Neoplasms
> Topoisomerase inhibitors
|
|
HYCAMTIN CAPSULES |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Topotecan (as HCl) 0.25mg, 1mg; caps. |
| Also |
|
• HYCAMTIN
|
| Indications |
|
Relapsed small cell lung cancer with prior complete or partial response and at least 45 days from the end of 1st line chemotherapy. |
| Children |
|
Not recommended. |
| Adults |
|
Swallow whole. 2.3mg/m2/day once daily for 5 consecutive days; repeat every 21 days. Dose adjustments: see literature. |
| Contraindications |
|
Severe bone marrow depression. Pregnancy (Cat.D). Nursing mothers. |
| Precautions |
|
Monitor peripheral blood cell counts; hold dose until neutrophils >1,000cells/mm3, platelets >100,000cells/mm3, and hemoglobin ≥9g/dL. Moderate to severe renal impairment. Caps: severe diarrhea; may need to reduce dose. IV: avoid extravasation. Elderly. |
| Interactions |
|
Myelosuppression potentiated with platinum agents. IV: Neutropenia potentiated by G-CSF. Caps: Avoid concomitant P-glycoprotein inhibitors (eg, cyclosporine A, elacridar, ketoconazole, ritonavir, saquinavir). |
| Adverse Reactions |
|
See literature. Neutropenia, leukopenia, thrombocytopenia, anemia, GI upset, anorexia, abdominal pain, stomatitis, headache, dyspnea, cough, pyrexia, alopecia, fatigue; infection, sepsis, neutropenic colitis (may be fatal). |
| How Supplied |
Single-use vials—1, 5
Caps—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
